10.1021/pr100529t.s005
Lawrence Kashat
Lawrence
Kashat
Anthony K.-C. So
Anthony K.-C.
So
Olena Masui
Olena
Masui
X. Simon Wang
X. Simon
Wang
Jun Cao
Jun
Cao
Xianwang Meng
Xianwang
Meng
Christina MacMillan
Christina
MacMillan
Laurie E. Ailles
Laurie E.
Ailles
K. W. Michael Siu
K.
W. Michael Siu
Ranju Ralhan
Ranju
Ralhan
Paul G. Walfish
Paul G.
Walfish
Secretome-Based Identification and Characterization of Potential Biomarkers in Thyroid Cancer
American Chemical Society
2010
CAL 62 cells
cytoplasmic expression
TPC
thyroid carcinomas
warranting future analysis
PTMA
thyroid cancer patients
NOD
thyroid cancer cell lines
protein
Thyroid CancerIn search
thyroid cancer biomarkers
2010-11-05 00:00:00
Journal contribution
https://acs.figshare.com/articles/journal_contribution/Secretome_Based_Identification_and_Characterization_of_Potential_Biomarkers_in_Thyroid_Cancer/2716588
In search of thyroid cancer biomarkers, proteins secreted by thyroid cancer cell lines, papillary-derived TPC-1 and anaplastic-derived CAL62, were analyzed using liquid chromatography−tandem mass spectrometry. Of 46 high-confidence identifications, 6 proteins were considered for verification in thyroid cancer patients’ tissue and blood. The localization of two proteins, nucleolin and prothymosin-α (PTMA), was confirmed in TPC-1 and CAL62 cells by confocal microscopy and immunohistochemically in xenografts of TPC-1 cells in NOD/SCID/γ mice and human thyroid cancers (48 tissues). Increased nuclear and cytoplasmic expression of PTMA was observed in anaplastic compared to papillary and poorly differentiated carcinomas. Nuclear expression of nucleolin was observed in all subtypes of thyroid carcinomas, along with faint cytoplasmic expression in anaplastic cancers. Importantly, PTMA, nucleolin, clusterin, cysteine-rich angiogenic inducer 61, enolase 1, and biotinidase were detected in thyroid cancer patients’ sera, warranting future analysis to confirm their potential as blood-based thyroid cancer markers. In conclusion, we demonstrated the potential of secretome analysis of thyroid cancer cell lines to identify novel proteins that can be independently verified in cell lines, xenografts, tumor tissues, and blood samples of thyroid cancer patients. These observations support their potential utility as minimally invasive biomarkers for thyroid carcinomas and their application in management of these diseases upon future validation.